Tg(tetO-TARDBP*A315T)13Lmit
Transgene Detail
|
Symbol: |
Tg(tetO-TARDBP*A315T)13Lmit |
Name: |
transgene insertion 13, Lars M Ittner |
MGI ID: |
MGI:5922010 |
Transgene: |
Tg(tetO-TARDBP*A315T)13Lmit Location: unknown
|
Alliance: |
Tg(tetO-TARDBP*A315T)13Lmit page
|
|
|
Transgene Type: |
|
Transgenic (Conditional ready, Humanized sequence, Inserted expressed sequence) |
Mutation: |
|
Insertion
|
|
|
Tg(tetO-TARDBP*A315T)13Lmit expresses
1 gene
Transgene expresses:
Organism |
Expressed Gene |
Homolog in Mouse |
Note |
human |
TARDBP (23435) |
|
Mutated human gene resulting in Ala315Thr substitution |
|
|
|
Mutation details: The human cDNA was engineered with a c.1077G>A point mutation, resulting in codon 315 changing from alanine to threonine (p.A315T or p.Ala315Thr). This mutation is associated with familial amyotrophic lateral sclerosis (ALS) in humans. A construct comprising the tetracycline inducible tetO promoter, the human cDNA and an SV40 poly signal, was injected into the pronuclei of fertilized C57BL/6 oocytes. Two lines, this line and numbers 6, were selected for further study.
(J:245760)
|
|
|
View phenotypes and curated references for all genotypes (concatenated display).
|
|
|
Mouse strains and cell lines
available from the International Mouse Strain Resource
(IMSR) |
Carrying this Mutation: |
Mouse Strains: 0 strains available
Cell Lines: 0 lines available
|
|
Original: |
J:245760 Ke YD, et al., Short-term suppression of A315T mutant human TDP-43 expression improves functional deficits in a novel inducible transgenic mouse model of FTLD-TDP and ALS. Acta Neuropathol. 2015 Nov;130(5):661-78 |
All: |
3 reference(s) |
|